BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoolmeester JK, Sciallis AP, Greipp PT, Hodge JC, Dal Cin P, Keeney GL, Nucci MR. Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors: A Potential Diagnostic Pitfall. Int J Gynecol Pathol 2015;34:576-83. [PMID: 26444253 DOI: 10.1097/PGP.0000000000000187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022:S0090-8258(22)00515-7. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Reference Citation Analysis]
2 Li C, Wang C. LG-ESSs and HG-ESSs: underlying molecular alterations and potential therapeutic strategies. J Zhejiang Univ Sci B 2021;22:633-46. [PMID: 34414699 DOI: 10.1631/jzus.B2000797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Suzuki S, Kurokawa R, Tsuruga T, Mori-Uchino M, Nishida H, Kato T, Abe H, Ushiku T, Amemiya S, Katayama A, Abe O. CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report. Radiol Case Rep 2021;16:2774-9. [PMID: 34367393 DOI: 10.1016/j.radcr.2021.06.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Akaev I, Yeoh CC, Rahimi S. Update on Endometrial Stromal Tumours of the Uterus. Diagnostics (Basel) 2021;11:429. [PMID: 33802452 DOI: 10.3390/diagnostics11030429] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
5 Micci F, Heim S, Panagopoulos I. Molecular pathogenesis and prognostication of "low-grade'' and "high-grade" endometrial stromal sarcoma. Genes Chromosomes Cancer 2021;60:160-7. [PMID: 33099834 DOI: 10.1002/gcc.22907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
6 Roy S, Laroche-Clary A, Verbeke S, Derieppe MA, Italiano A. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers (Basel) 2020;12:E2253. [PMID: 32806555 DOI: 10.3390/cancers12082253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Rodriguez Pena MDC, Gordetsky J, Greipp PT, Wei S, Martignoni G, Netto GJ, Harada S, Prieto Granada CN. Rare MDM2 amplification in a fat-predominant angiomyolipoma. Virchows Arch 2020;477:661-6. [PMID: 32409886 DOI: 10.1007/s00428-020-02813-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hirsch MS, Watkins J. A Comprehensive Review of Biomarker Use in the Gynecologic Tract Including Differential Diagnoses and Diagnostic Pitfalls. Adv Anat Pathol 2020;27:164-92. [PMID: 31149908 DOI: 10.1097/PAP.0000000000000238] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
9 Kommoss FK, Chang KT, Stichel D, Banito A, Jones DT, Heilig CE, Fröhling S, Sahm F, Stenzinger A, Hartmann W, Mechtersheimer G, Sinn HP, Schmidt D, Kommoss F, von Deimling A, Koelsche C. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. J Pathol Clin Res 2020;6:178-84. [PMID: 32352245 DOI: 10.1002/cjp2.165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
10 Micci F, Davidson B. Molecular Genetics of Uterine Sarcomas. eLS 2019. [DOI: 10.1002/9780470015902.a0028464] [Reference Citation Analysis]
11 Howitt BE, Nucci MR. Uterine Mesenchymal Lesions. Gynecologic and Obstetric Pathology, Volume 2 2019. [DOI: 10.1007/978-981-13-3019-3_1] [Reference Citation Analysis]
12 Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 2018;9:33232-43. [PMID: 30237864 DOI: 10.18632/oncotarget.26075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
13 Gupta R, Cooper WA, Selinger C, Mahar A, Anderson L, Buckland ME, O'Toole SA. Fluorescent In Situ Hybridization in Surgical Pathology Practice. Adv Anat Pathol 2018;25:223-37. [PMID: 29727321 DOI: 10.1097/PAP.0000000000000194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Tsuyoshi H, Yoshida Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci 2018;109:1743-52. [PMID: 29660202 DOI: 10.1111/cas.13613] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
15 Howitt BE, Nucci MR, Quade BJ. Uterine Mesenchymal Tumors. Diagnostic Gynecologic and Obstetric Pathology 2018. [DOI: 10.1016/b978-0-323-44732-4.00020-0] [Reference Citation Analysis]
16 Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol 2017;10:133. [PMID: 28673313 DOI: 10.1186/s13045-017-0500-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 167] [Article Influence: 32.4] [Reference Citation Analysis]